Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III study of monotherapy by gemcitabine or vinorelbine comparing to doublet by carboplatin and paclitaxel among elderly patients with stage IIIB/IV NSCLC (obligatory second-line by erlotinib).

Trial Profile

Phase III study of monotherapy by gemcitabine or vinorelbine comparing to doublet by carboplatin and paclitaxel among elderly patients with stage IIIB/IV NSCLC (obligatory second-line by erlotinib).

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Oct 2013

At a glance

  • Drugs Carboplatin (Primary) ; Erlotinib (Primary) ; Paclitaxel (Primary) ; Gemcitabine; Vinorelbine
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Oct 2012 Results reporting outcomes for second-line erlotinib presented at the 37th Congress of the European Society for Medical Oncology.
    • 08 Aug 2011 Primary endpoint 'Overall-survival' has been met.
    • 08 Aug 2011 Results after 30.3 months of follow-up published in the Lancet.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top